AL037 / Alector - LARVOL DELTA

Recent Program Updates (GlobeNewswire) - "Alector continues to advance AL037/AL137...The company is targeting an IND submission in Q1 2027...Alector continues to advance AL064/AL164, its ABC-enabled tau siRNA program for the treatment of AD and other tauopathies....In addition to AL164, the company is advancing early-stage siRNA programs toward lead candidate selection, including ADP062-ABC, an alpha-synuclein siRNA for PD and ADP065-ABC, an NLRP3 siRNA for multiple neurodegenerative conditions, reflecting the broad applicability of the ABC platform across disease mechanisms."

IND • Pipeline update • Alzheimer's Disease • Parkinson's Disease

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs (GlobeNewswire) - "The event will include a review of latozinemab, currently being evaluated in a pivotal Phase 3 trial for frontotemporal dementia due to a GRN gene mutation, and AL101, which is in a Phase 2 trial for early Alzheimer’s disease (AD). In addition, the company will present preclinical data on lead candidates for its ABC–enabled programs, including its brain-penetrant anti-amyloid beta antibody program for AD, and its brain-penetrant engineered GCase-enzyme replacement therapy for Parkinson’s disease. The event will also highlight progress in Alector’s ABC-enabled siRNA programs, which expand the platform’s reach across different cargos for the treatment of neurodegenerative diseases."

Clinical • Preclinical • Alzheimer's Disease • Frontotemporal Lobar Degeneration • Gaucher Disease • Lewy Body Disease • Parkinson's Disease

Recent Clinical Updates (GlobeNewswire) - "The global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in early Alzheimer’s disease (AD) is ongoing, with enrollment completed in April 2025 and trial completion expected in 2026....Alector is currently evaluating potential candidates and continues to target clinical entry for ADP037-ABC and ADP050-ABC in 2026, pending resource allocation, lead candidate selection, and the results of preclinical studies."

New trial • Trial completion date • Alzheimer's Disease • Gaucher Disease • Lewy Body Disease • Parkinson's Disease